Discover open access scientific publications

Search, annotate, share and cite publications

Publications by C Doyen

Phase I/Ii Study of 2-Chloro-2′-Deoxyadenosine With Cyclophosphamide in Patients With Pretreated B Cell Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin’s Lymphoma

Leukemia

English

Related publications

A Phase I/Ii Study of Rituximab and Etanercept in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

English

5'-Esters of 2'-Deoxyadenosine and 2-Chloro-2'-Deoxyadenosine With Cell Differentiation-Provoking Agents.

Acta Biochimica Polonica

English

Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

Hematological Oncology

English

A Phase II Study of Bortezomib Added to Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Indolent Non-Hodgkin's Lymphoma

British Journal of Haematology

Hematology

2015

English

SPIReL: PHASE 2 STUDY DPX-SURVIVAC WITH INTERMITTENT LOW DOSE CYCLOPHOSPHAMIDE AND PEMBROLIZUMAB IN PATIENTS WITH RECURRENT/REFRACTORY DIFFUSE LARGE B-Cell LYMPHOMA

Hematological Oncology

English

A Phase II Study to Evaluate Lenalidomide in Combination With Metronomic-Dose Cyclophosphamide in Patients With Heavily Pretreated Classical Hodgkin Lymphoma

English

Experience With Ibrutinib in Patients With Refractory and Recurrent B-Cell Chronic Lymphocytic Leukemia

Medical Council

2017

English

The Use of Low-Dose Alemtuzumab in Pretreated B-Cell Chronic Lymphocytic Leukemia

English

Induction of Apoptosis by 2-Chlorodeoxyadenosine in B Cell Chronic Lymphocytic Leukemia

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by C Doyen

Phase I/Ii Study of 2-Chloro-2′-Deoxyadenosine With Cyclophosphamide in Patients With Pretreated B Cell Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin’s Lymphoma

Related publications

A Phase I/Ii Study of Rituximab and Etanercept in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

5'-Esters of 2'-Deoxyadenosine and 2-Chloro-2'-Deoxyadenosine With Cell Differentiation-Provoking Agents.

Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

A Phase II Study of Bortezomib Added to Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Indolent Non-Hodgkin's Lymphoma

SPIReL: PHASE 2 STUDY DPX-SURVIVAC WITH INTERMITTENT LOW DOSE CYCLOPHOSPHAMIDE AND PEMBROLIZUMAB IN PATIENTS WITH RECURRENT/REFRACTORY DIFFUSE LARGE B-Cell LYMPHOMA

A Phase II Study to Evaluate Lenalidomide in Combination With Metronomic-Dose Cyclophosphamide in Patients With Heavily Pretreated Classical Hodgkin Lymphoma

Experience With Ibrutinib in Patients With Refractory and Recurrent B-Cell Chronic Lymphocytic Leukemia

The Use of Low-Dose Alemtuzumab in Pretreated B-Cell Chronic Lymphocytic Leukemia

Induction of Apoptosis by 2-Chlorodeoxyadenosine in B Cell Chronic Lymphocytic Leukemia